Letter to the Editor

Brugada Syndrome, Epilepsy and Pemphigus Vulgaris

Authors: Marzia Caproni, MD, Daniele Torchia, MD, Leonardo Parigi, MD, Paolo Fabbri, MD

Abstract

To the Editor:


A 67-year-old man was affected for 18 years by pemphigus vulgaris; he was maintained on oral methylprednisolone 8 mg daily. He was also taking enalapril, potassium canrenoate and butizide for arterial hypertension. Prophylactic therapy with phenytoin 100 mg and lamotrigin 100 mg daily had been established several years before because of generalized idiopathic epilepsy.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;111:659–670.
 
2.Fauchier L, Babuty D, Cosnay P. Epilepsy, Brugada syndrome and the risk of sudden unexpected death. J Neurol 2000;247:643–644.
 
3.Dourmishev AL, Rahman MA. Phenobarbital-induced pemphigus vulgaris. Dermatologica 1986;173:256–258.
 
4.Sehgal VN, Srivastava G. Corticosteroid-unresponsive pemphigus vulgaris following antiepileptic therapy. Int J Dermatol 1988;27:258.
 
5.Patterson CR, Davies MG. Carbamazepine-induced pemphigus. Clin Exp Dermatol 2003;28:98–99.